X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/gemoab-announces-publication-of-clinical-data-from-ongoing-phase-i-study-of-their-lead-asset-unicar-t-cd123-in-relapsedrefractory-aml-in-blood-301238246.html
https://www.prnewswire.com/news-releases/gemoab-announces-presentation-of-translational-data-from-ongoing-phase-i-clinical-study-of-their-lead-asset-unicar-t-cd123-in-relapsedrefractory-aml-at-the-upcoming-2021-aacr-annual-meeting-301225762.html
https://www.prnewswire.com/news-releases/gemoab-announces-unicar-t-cd123-data-from-its-ongoing-phase-i-study-in-patients-with-relapsedrefractory-aml-rraml-to-be-presented-at-virtual-3rd-eha-ebmt-european-car-t-cell-meeting-301221278.html
https://www.prnewswire.com/news-releases/gemoab-announces-unicar-t-cd123-data-from-its-ongoing-phase-i-study-in-patients-with-relapsedrefractory-aml-rraml-to-be-presented-at-virtual-3rd-eha-ebmt-european-car-t-cell-meeting-301221278.html
https://www.prnewswire.com/news-releases/gemoab-announces-clinical-data-presentations-on-their-lead-asset-unicar-t-cd123-in-relapsedrefractory-aml-at-the-upcoming-eha-ebmt-3rd-european-car-t-cell-meeting-301201927.html
https://www.prnewswire.com/news-releases/gemoab-and-intellia-therapeutics-enter-into-research-collaboration-and-licensing-agreement-on-next-generation-cellular-immunotherapy-based-on-proprietary-revcar-and-crisprcas9-genome-editing-platforms-301096049.html
https://www.prnewswire.com/news-releases/gemoab-announces-data-presentations-supporting-key-features-of-its-unicar-platform-at-the-upcoming-american-association-for-cancer-research-aacr-meeting-ii-301060027.html
https://www.prnewswire.com/news-releases/gemoab-announces-data-presentations-supporting-key-features-of-its-unicar-platform-at-the-upcoming-american-association-for-cancer-research-aacr-meeting-ii-301060027.html
Market Place
Share 
